Saikosaponin B2

Saikosaponin B2 at a Glance

Saikosaponin B2 (SSb2) is a secondary oleanane triterpenoid saponin of Bupleurum (chai hu) root. Unlike the three principal saikosaponins — saikosaponin A, saikosaponin C and saikosaponin D — it is not a major native constituent of the fresh plant. It is a processing artifact: the heterocyclic-diene rearrangement product formed from the native saikosaponin d under acid and heat, so it accumulates in processed root rather than raw material ^{2Reference 2Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →}.

Its best-documented and most distinctive activity is antiviral — specifically as an efficient hepatitis-C virus (HCV) entry inhibitor that blocks viral attachment by targeting the E2 glycoprotein ^{1Reference 1Lin LT et al. · 2015Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entryView study →}. Beyond that it carries the saikosaponin class’s anti-inflammatory (NF-κB-suppressing) signal ^{4Reference 4Shin JS et al. · 2019Saikosaponin B2 suppresses inflammatory responses through IKK/IκBα/NF-κB signaling inactivation in LPS-induced RAW 264.7 macrophagesView study →} and a small preclinical liver-cancer literature ^{5,6Reference 5Lei C et al. · 2023Saikosaponin-b2 inhibits primary liver cancer by regulating the STK4/IRAK1/NF-κB pathwayView study →Reference 6Zhu Y et al. · 2024Saikosaponin-b2 regulates the proliferation and apoptosis of liver cancer cells by targeting the MACC1/c-Met/Akt signalling pathwayView study →}.

The honest posture is the same as for its siblings: all of this is preclinical, there are no human trials of the isolate, and every clinical use of Bupleurum is of the whole herb or a multi-herb formula. What sets SSb2 apart from the toxic parents is that it is the less-cytotoxic degradation product — the endpoint that traditional vinegar-processing is partly designed to produce.

A Processing Artifact — SSb2 vs. Its Native Parent

This is the page’s load-bearing point, and the reason SSb2 behaves differently from the principal saikosaponins. The native saikosaponins a, c and d are type-I “epoxy-ether” saponins, defined by a strained 13β,28-epoxy-ether bridge in the aglycone. Saikosaponin B2 is a type-II “heterocyclic-diene” saponin: under acidic (and heat) conditions the 13,28-epoxy ring of saikosaponin d opens — protonation generates a C13 carbocation stabilised by the π-electrons of the C11–C12 double bond — and the aglycone rearranges into a conjugated diene with a characteristic UV shift toward ~252 nm ^{2Reference 2Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →}.

The practical consequences are threefold:

• It is a marker of processed, not raw, root. Vinegar-/wine-frying and ordinary extraction, storage and heating convert the labile epoxy-ether parents into the b-series (saikosaponin a → saikosaponin b1; saikosaponin d → saikosaponin b2) ^{2Reference 2Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →}. Traditional processing deliberately lowers the toxic epoxy-ether saponins, so the b-series is part of the detoxified profile.
• It loses the parents’ toxic pharmacophore. The 13,28-epoxy-ether is tied to the SERCA-inhibitory, cardio-/hepatotoxic behaviour of saikosaponins a and d; removing it is why SSb2 is consistently reported as less cytotoxic than its parents ^{3Reference 3Zhu Y et al. · 2023ReviewPharmacological properties and derivatives of saikosaponins — a review of recent studiesView study →}.
• It is a distinct molecule, not a stand-in. SSb2’s antiviral entry-inhibition is its own property, not inherited from saikosaponin d, and should not be read across to the native saponins.

What It's Used For

The evidence base is small and entirely preclinical, but it has one unusually well-defined signal (HCV entry inhibition) alongside the class-level anti-inflammatory and anticancer themes.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. No human isolate data, so scores stay modest by design.

01Antiviral / HCV Entry InhibitionShaky40%E2-targeted entry blockade at non-cytotoxic doses, multi-genotype + primary hepatocytes ^{1Reference 1Lin LT et al. · 2015Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entryView study →}

02Anti-Inflammatory / ImmunomodulatoryShaky32%IKK/IκBα/NF-κB suppression in LPS macrophages ^{4Reference 4Shin JS et al. · 2019Saikosaponin B2 suppresses inflammatory responses through IKK/IκBα/NF-κB signaling inactivation in LPS-induced RAW 264.7 macrophagesView study →}

03Anticancer (Liver)Shaky28%Two rodent/cell mechanisms — STK4/IRAK1/NF-κB and MACC1/c-Met/Akt ^{5,6Reference 5Lei C et al. · 2023Saikosaponin-b2 inhibits primary liver cancer by regulating the STK4/IRAK1/NF-κB pathwayView study →Reference 6Zhu Y et al. · 2024Saikosaponin-b2 regulates the proliferation and apoptosis of liver cancer cells by targeting the MACC1/c-Met/Akt signalling pathwayView study →}

Mechanisms

Pharmacokinetics

No verified human or dedicated animal pharmacokinetic study of isolated saikosaponin B2 exists. As a large oleanane triterpenoid saponin it carries the expected class liabilities — poor passive membrane permeability, extensive gastric/gut-microbial hydrolysis, and low oral bioavailability ^{3Reference 3Zhu Y et al. · 2023ReviewPharmacological properties and derivatives of saikosaponins — a review of recent studiesView study →}. There is a compound-specific twist: SSb2 is itself an acid-hydrolysis product of saikosaponin d ^{2Reference 2Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →}, so the same gut/acid biotransformation that degrades the native saponins is a plausible route by which b-series products arise in vivo. The practical implication is standard for this class: the in-vitro antiviral and anti-inflammatory concentrations are unlikely to be reached from oral whole-herb intake, and the HCV result — an entry effect at the cell surface — still awaits any in-vivo confirmation ^{1,3Reference 1Lin LT et al. · 2015Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entryView study →Reference 3Zhu Y et al. · 2023ReviewPharmacological properties and derivatives of saikosaponins — a review of recent studiesView study →}.

Clinical Trials

There are no human trials of isolated saikosaponin B2. All Bupleurum clinical experience is with the whole herb or a multi-herb formula (e.g. Xiao Chai Hu Tang / Sho-saiko-to), which cannot be attributed to this single, largely processing-derived saponin.

Last checked: July 2026.

Isolate vs. Plant Studies

Unusually for a saikosaponin, the flagship result here is on the isolated molecule: the HCV entry-inhibition, anti-inflammatory NF-κB and liver-cancer mechanisms were all obtained with purified SSb2 in vitro (and, for the cancer work, in mice), not with whole extract ^{1,4,5,6Reference 1Lin LT et al. · 2015Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entryView study →Reference 4Shin JS et al. · 2019Saikosaponin B2 suppresses inflammatory responses through IKK/IκBα/NF-κB signaling inactivation in LPS-induced RAW 264.7 macrophagesView study →Reference 5Lei C et al. · 2023Saikosaponin-b2 inhibits primary liver cancer by regulating the STK4/IRAK1/NF-κB pathwayView study →Reference 6Zhu Y et al. · 2024Saikosaponin-b2 regulates the proliferation and apoptosis of liver cancer cells by targeting the MACC1/c-Met/Akt signalling pathwayView study →}. That is a methodological strength — the activity is attributable to this compound. The countervailing caveat is the standard one: no human clinical evidence exists for the isolate, and Bupleurum’s real-world use is always the whole (usually processed) root or formula, where SSb2 is a minor, variable component that depends heavily on how the root was processed ^{2,3Reference 2Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →Reference 3Zhu Y et al. · 2023ReviewPharmacological properties and derivatives of saikosaponins — a review of recent studiesView study →}.

Prevalence in Nature

Saikosaponin B2 is found in the genus Bupleurum (chai hu / Radix Bupleuri), the same source as the principal saikosaponins ^{3,7Reference 3Zhu Y et al. · 2023ReviewPharmacological properties and derivatives of saikosaponins — a review of recent studiesView study →Reference 7Ashour ML · 2011ReviewGenus Bupleurum: a review of its phytochemistry, pharmacology and modes of actionView study →}. The saikosaponin class as a whole runs to roughly a few percent of dry root, with more than a half-dozen members and species-, provenance- and processing-dependent content ^{7Reference 7Ashour ML · 2011ReviewGenus Bupleurum: a review of its phytochemistry, pharmacology and modes of actionView study →}. SSb2 itself, however, is best understood as a secondary saponin: it is largely absent from fresh root and is generated from native saikosaponin d during acid/heat processing, extraction and storage ^{2Reference 2Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →}, so it is enriched in vinegar-/heat-processed Radix Bupleuri rather than raw material. No reliable quantified natural-abundance figure for SSb2 specifically was available — the concentration story is a documented gap.

Discovery & Synthesis

Saikosaponin B2 was not characterised as a fresh-plant isolate in the way its principal siblings were; it entered the literature as a degradation/processing product of the native saikosaponins. It is now well established that acid and heat convert the epoxy-ether saponins into the b-series — saikosaponin b2 being the heterocyclic-diene rearrangement product of saikosaponin d — a transformation reproduced and mechanistically detailed under controlled acid-hydrolysis conditions, where SSb2 was identified among the acid-hydrolysis products of the saikosaponin scaffold ^{2Reference 2Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →}. A dedicated total synthesis of saikosaponin B2 is not well documented; in practice the compound is obtained by isolation from processed root or by acid treatment of the parent saponins rather than by de novo synthesis.

Patents: not yet researched.

Toxicity & Safety

Saikosaponin B2 carries a low flag — the same tier as its mild sibling saikosaponin C, and a step below the toxic epoxy-ether parents saikosaponin A and saikosaponin D (both moderate). The reasoning is molecule-specific, not a blanket downgrade: SSb2 lacks the 13,28-epoxy-ether pharmacophore tied to the parents’ SERCA inhibition and organ toxicity, it is consistently reported as less cytotoxic than saikosaponins a and d, its antiviral activity occurs at non-cytotoxic concentrations, and it is the detoxified endpoint of the traditional vinegar-processing that lowers the more hazardous saponins ^{1,2,3Reference 1Lin LT et al. · 2015Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entryView study →Reference 2Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →Reference 3Zhu Y et al. · 2023ReviewPharmacological properties and derivatives of saikosaponins — a review of recent studiesView study →}. It is still a saponin, however, and the class cautions apply.

Safety at a Glance

✅ Low / no toxicity

• The less-toxic processing product. SSb2 lacks the epoxy-ether pharmacophore behind saikosaponin a/d’s SERCA-mediated cardio-/hepatotoxicity and is reported as less cytotoxic than its parents.
• Active at non-cytotoxic concentrations. The HCV entry-inhibition was demonstrated below cytotoxic doses.
• Still a hemolytic saponin. Saikosaponins are inherently hemolytic at high concentration — a generic class property.
• Class hepatotoxicity context. SSb2 travels in Bupleurum, and the saikosaponin class (led by the dose-dependent hepatotoxin saikosaponin d) and its formulas (Sho-saiko-to) carry real hepatotoxicity/interstitial-pneumonia reports; formula-level cautions still apply.
• No dedicated isolate safety dataset. No reproductive, repeat-dose or human safety package for pure SSb2 — absence of data is not evidence of safety.

Full Safety & Interactions Detail

Saikosaponin B2 is flagged low, and the justification is structural. The principal, more toxic saikosaponins a and d owe their SERCA-inhibitory, cardio- and hepatotoxic behaviour to the strained 13,28-epoxy-ether in the aglycone; SSb2 is the heterocyclic-diene rearrangement product in which that bridge has opened, and it is correspondingly less cytotoxic than its parents ^{2,3Reference 2Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →Reference 3Zhu Y et al. · 2023ReviewPharmacological properties and derivatives of saikosaponins — a review of recent studiesView study →}.

Its documented pharmacology reinforces this: the HCV entry-inhibition was obtained at non-cytotoxic concentrations ^{1Reference 1Lin LT et al. · 2015Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entryView study →}, and in a tumour-bearing model SSb2 lowered serum AST/ALT/LDH rather than raising them ^{5Reference 5Lei C et al. · 2023Saikosaponin-b2 inhibits primary liver cancer by regulating the STK4/IRAK1/NF-κB pathwayView study →}.

This places it alongside saikosaponin C at low, below saikosaponins a and d.

The cautions that remain are class-level, not molecule-specific. Saikosaponins are hemolytic at high concentration (a generic saponin property); the class includes the dose-dependent hepatotoxin saikosaponin d, and Bupleurum-containing formulas such as Sho-saiko-to carry well-known hepatotoxicity and interstitial-pneumonia reports at the formula level ^{7Reference 7Ashour ML · 2011ReviewGenus Bupleurum: a review of its phytochemistry, pharmacology and modes of actionView study →}.

No dedicated reproductive, genotoxicity or repeat-dose dataset exists for isolated SSb2, and no human safety study of the isolate has been performed — so the low flag reflects the available cytotoxicity evidence, not a full toxicology package. Any reproductive-safety and drug-interaction decisions belong to the whole-herb or product page, where intake is decided, not to this molecule page.

Dosage

There is no established or safe human dose. Saikosaponin B2 has never been dosed as an isolate in humans, and every figure in the literature is an in-vitro (µM) or animal-research concentration, not a recommendation. Any real-world exposure is only as a minor fraction of whole chai hu root or formula — and because SSb2 is largely a processing product, that fraction depends heavily on how the root was prepared (raw vs. vinegar-/heat-processed) ^{2,7Reference 2Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →Reference 7Ashour ML · 2011ReviewGenus Bupleurum: a review of its phytochemistry, pharmacology and modes of actionView study →}. These are research concentrations studied in the laboratory and are not a personal recommendation.

References

1. Lin LT, Chung CY, Hsu WC, Chang SP, Hung TC, Shields J, Russell RS, Lin CC, Li CF, Yen MH, Tyrrell DL, Lin CC, Richardson CD (2015). Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. Journal of Hepatology. https://pubmed.ncbi.nlm.nih.gov/25450204/
2. Li J, Xu Q, Jiang H (2016). Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditions. Molecules. https://pubmed.ncbi.nlm.nih.gov/27649123/
3. Zhu Y, et al. (2023). Pharmacological properties and derivatives of saikosaponins — a review of recent studies. Journal of Pharmacy and Pharmacology. https://pubmed.ncbi.nlm.nih.gov/37307427/
4. Shin JS, Im HT, Lee KT (2019). Saikosaponin B2 suppresses inflammatory responses through IKK/IκBα/NF-κB signaling inactivation in LPS-induced RAW 264.7 macrophages. Inflammation. https://pubmed.ncbi.nlm.nih.gov/30251218/
5. Lei C, Gao Z, Lv X, Zhu Y, Li R, Li S (2023). Saikosaponin-b2 inhibits primary liver cancer by regulating the STK4/IRAK1/NF-κB pathway. Biomedicines. https://pubmed.ncbi.nlm.nih.gov/37893233/
6. Zhu Y, et al. (2024). Saikosaponin-b2 regulates the proliferation and apoptosis of liver cancer cells by targeting the MACC1/c-Met/Akt signalling pathway. Advances in Pharmacological and Pharmaceutical Sciences. https://pubmed.ncbi.nlm.nih.gov/39544485/
7. Ashour ML, Wink M (2011). Genus Bupleurum: a review of its phytochemistry, pharmacology and modes of action. Journal of Pharmacy and Pharmacology. https://pubmed.ncbi.nlm.nih.gov/21749378/

View all 7 references▾